Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Antidepressant could treat recurrent prostate cancer

Key clinical point: The monoamine oxidase inhibitor phenelzine appears active and generally well tolerated in patients with biochemically recurrent, nonmetastatic, castrate-sensitive prostate cancer.

Major finding: A quarter of patients (5/20) achieved a prostate-specific antigen reduction of at least 30% from baseline, and two patients (10%) had a reduction of at least 50% from baseline. Serious toxicities included one case of grade 4 hypertension and two cases of grade 3 syncope.

Study details: A single-arm, phase 2 trial of 20 patients with biochemically recurrent, nonmetastatic, castrate-sensitive prostate cancer.

Disclosures: The study was funded by the USC-Taiwan Center for Translational Research and the National Cancer Institute. The authors disclosed financial affiliations with Amgen, Astellas, AstraZeneca, Bayer, and other companies.

Citation:

Gross ME et al. Prostate Cancer Prostatic Dis. 2020 Mar 3. doi: 10.1038/s41391-020-0211-9.